# Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH) Response from Indigenous Innovators Collaborative

> **NIH FDA U01** · AMERICANS FOR INDIAN OPPORTUNITY · 2024 · $100,000

## Abstract

Project Summary/Abstract 30 lines of text
 
With a collaborative approach grounded in Indigenous core cultural values, the Indigenous
Innovators Collaborative (IIC) team will engage in community-based participatory research
study to address the FDA priorities as outlined in FDA OMHHE Health Equity Innovation Award:
Racial and Ethnic Minority Acceleration Consortium for Health Equity (REACH) funding
opportunity. The IIC seeks to engage American Indian and Alaska Native (AIAN) communities,
stakeholders, researchers in an exploration of clinical trials and promote cultural knowledge in
understanding clinical trials in Indian Country. The IIC consists of core partners that form the
Administrative Core (AC) of this project, including: (1) Americans for Indian Opportunity (AIO),
which serves as the fiscal agent/grant administrator; (2) Co-Investigator 1: Dr. Myra Parker
(Three Affiliated Tribes), University of Washington; (3) Co-Investigator 2: Dr. Billie Jo Kipp
(Blackfeet), Natives in Philanthropy; (4) Principle Investigator: Stephine Poston (Pueblo of
Sandia), Poston & Associates, LLC; and, (5) the United Tribes Technical College (UTTC), an
accredited, land-grant tribal college located in Bismarck, North Dakota, that serves the five
reservations in ND and tribal members across the U.S. UTTC has provided higher education
support to over 10,000 AI students from over 75 tribes. We propose to expand this effort to
implement an exploratory study that would employ a mixed methods approach to improve
understandings of AIAN perceptions of clinical trials and gene therapy across multiple regions of
the U.S. Our aims include:
 1. Specific Aim 1 – Partner with local tribal colleges to assess AIAN community
 knowledge, concerns, and beliefs about clinical trials and gene therapy within the 12 IHS
 regions using a mixed methods approach.
 a. Hypothesis 1 – AIAN community knowledge, concerns, and beliefs about clinical
 trials and gene therapy will vary across IHS regions and will reflect local tribal
 cultural understandings.
2. Specific Aim 2 – Identify barriers and supports for clinical trials and gene therapy
 among AIAN within the 12 IHS regions by collecting qualitative data from AIAN
 providers, researchers, and public health experts.
 a. Hypothesis 2 – Barriers and supports for clinical trials and gene therapy among
AIAN will vary by IHS Region and tribal cultures.

## Key facts

- **NIH application ID:** 11173537
- **Project number:** 3U01FD007981-02S2
- **Recipient organization:** AMERICANS FOR INDIAN OPPORTUNITY
- **Principal Investigator:** Billie Kipp
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** FDA
- **Fiscal year:** 2024
- **Award amount:** $100,000
- **Award type:** 3
- **Project period:** 2023-06-05 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11173537

## Citation

> US National Institutes of Health, RePORTER application 11173537, Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH) Response from Indigenous Innovators Collaborative (3U01FD007981-02S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11173537. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*